The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Challenges and next steps for CAR-T in B-cell lymphomas
Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the biggest challenges and next steps for chimeric antigen receptor T-cell (CAR-T) therapy for patients with B-cell lymphomas. Dr Roddie talks on challenges around manufacturing and the long wait time associated with the manufacturing period, commenting on studies which aim to manufacture CAR T-cells within 24 hours and the potential of developing and using allogeneic CAR-T cells. Dr Roddie also highlights the poor responses of some patients, the need to develop a deeper understanding on the causes of non-response to CAR-T, and the need for improved bridging strategies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
